All News

In this episode, host Amy Pearlman, MD, sits down with Bruce R. Kava, MD, for a a discussion on his career path from oncologic surgery to sexual medicine, revision penile prosthetics, and cancer survivorship.

FDA lifts boxed warnings on 6 menopausal hormone therapies following a review of the evidence on risks and benefits.

A newly published meta-analysis found that adding metastasis-directed therapy to standard-of-care was associated with extended progression-free survival in oligometastatic prostate cancer, without adding significant safety risks.

Beyond clinical care, this episode highlights the evolving role of advanced practice providers in urology.

A major focus of the episode is reconstructive urology, particularly the unpredictable and long-term effects of pelvic radiation.

The phase 2 Alliance A222001 trial showed that obybuynin led to clinically meaningful improvements in hot flash frequency and quality of life.

The findings offer insights into how treatment may be optimized using PSMA-PET/CT results.

The following FAQs highlight key guideline recommendations relevant to clinicians regarding the early detection of prostate cancer.

In this episode, host Amy Pearlman, MD, sits down with Emad Ibrahim, MD, HCLD, to discuss sexual and reproductive health in patients with spinal cord injury.

The conversation explores the growing role of at-home semen testing kits as screening tools, their advantages in accessibility and privacy, and their limitations compared with in-lab testing.

The study is designed to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of NEO-811 in ccRCC.

The sildenafil oral film is expected to be commercially available in the US in March 2026.

URO-1’s FDA-cleared SUREcore and coreCARE prostate biopsy devices have been adopted at multiple Novant Health hospitals as part of a systemwide value analysis.

The conversation explores evolving strategies that have further lowered infection risk, including no-touch principles, chlorhexidine skin preparation, antibiotic and customizable implant coatings, and growing interest in antiseptic-based solutions rather than antibiotics alone.

At 24 months, apalutamide demonstrated a statistically significant improvement in OS vs darolutamide without concurrent docetaxel.

Amy Pearlman, MD, sits down with Katherine A. Amin, MD, to discuss the evolving landscape of female pelvic medicine, overactive bladder management, and fellowship training.

The application is seeking approval of Signatera CDx as a companion diagnostic to select patients with MIBC for treatment with adjuvant atezolizumab.

A recap of the FDA submissions and regulatory decisions in urology from January 2025.

ANDROMEDA is looking to build on previous findings from the LUNAR trial in recurrent, oligometastatic prostate cancer.

The conversation highlights the steady pace of innovation in urogynecology.

Cooled laser focal therapy with the ProFocal Device showed promising cancer control in patients with localized prostate cancer.

In this episode, Amy Pearlman, MD, speaks with Phillip M. Pierorazio, MD, about integrating mindfulness and wellness into a demanding surgical career and the evolving complexities of modern prostate cancer care.

The combination was tolerable and demonstrated promising early efficacy as a 3rd-line option for patients with mCRPC.

Beyond operative technique, the episode addresses patient counseling, including expectations around fertility, anejaculation, and postoperative complications such as chyle leak.

The report highlights key trends in cancer treatment and outcomes, including detailed analyses across 3 cancer types: prostate, esophageal, and melanoma.

AVA-291 is a differentiated formulation of testosterone designed to retain androgen activity while resisting aromatization.